Kintara (KTRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Kintara (KTRA)

Kintara Therapeutics (KTRA) is striving for high scalability by developing treatments for resistant tumors with the potential for software-like profits through alliances with pharma behemoths. A stable investor pool supports the company during its transition to cellular vaccines. This chart reflects an asset value of 0.00, while Kintara Therapeutics (KTRA) minimizes costs by outsourcing production and testing to third-party contractors.

KTRA Kintara Therapeutics Inc: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/15/2026

KTRA (Kintara Therapeutics Inc): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Kintara Therapeutics|KTRA - Fair Value Consensus
- market capitalization indicators:
Market Value Kintara Pharma|KTRA - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Kintara Therapeutics|KTRA - Accounting Capitalization|Market Capitalization to Book Value Ratio kintara.com|KTRA - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Kintara Therapeutics|KTRA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Kintara|KTRA - Company Debts|Debt to Book Capitalization Ratio Kintara Pharma|KTRA - Long-Term Debt|Company Short-Term Debts Kintara Therapeutics|Quick Liquidity Indicator kintara.com
- business earnings and investment ratios data:
KTRA - Company Net Income|Future Profit Kintara Therapeutics|KTRA - Company Value to Net Income|Projected Price to Earnings Kintara Therapeutics|KTRA - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Kintara Therapeutics Inc|KTRA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Kintara Therapeutics|KTRA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months kintara.com|KTRA - Earnings per share increase in current year|Earnings growth forecast for next year Kintara Therapeutics
- sales and revenue indicators:
KTRA - Revenue and Sales Volume|Company Projected Revenue Kintara|KTRA - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple Kintara Pharma
Summary company analytics:KTRA (Kintara Therapeutics Inc)
Original product of Kintara Therapeutics, Inc.

The merger of Kintara Therapeutics (KTRA) with an oncology platform mitigates the risks of a single-product model, transforming the asset structure. The EV/EBITDA trend on this chart allows for an assessment of this rebalancing efficiency relative to market capitalization and debt. This metric measures the business payback period via operating profit before interest, taxes, depreciation, and amortization, determining the fair value of shares within the high-risk biotech asset category.

Competitor analysis

Incyte Corporation - Enterprise Value to EBITDA Ratio|hutch-med.com (HCM) - Company Value to EBITDA|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Day One Biopharmaceuticals, Inc.|Monopar Therapeutics (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (i-mabbiopharma.com) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio fennecpharma.com (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences, Inc CHRS|Corbus Pharmaceuticals, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc.|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Lixte Biotechnology Holdings LIXT|Enterprise Value to EBITDA Ratio CTXR|Company Value to EBITDA Cellectar Biosciences CLRB|Enterprise Value to EBITDA Ratio BLRX (BioLineRx Ltd.)|CANF (Can-Fite BioPharma Ltd.) - Business Value to Operating Income Before Depreciation|Aprea Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio KZIA (Kazia)|Silexion Therapeutics - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation NCNA (nucana.com)|CMRX: EV/EBITDA Multiple|Company Value to EBITDA cyclacel.com (CYCC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization g1therapeutics.com|KRON: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Corp (PRTG)